8-K – Page 271 – China Stock Advice

AMC [AMC ENTERTAINMENT] 8-K: AMC THEATRES TO ACQUIRE CARMIKE CINEMAS, CREATING LARGEST

[AMC THEATRES TO ACQUIRE CARMIKE CINEMAS, CREATING LARGEST CHAIN OF MOVIE THEATRES IN THE U.S. AND THE WORLD Combines Highly Complementary Theatre Circuits to Expand Platform for AMCs Guest Experience and Strategic Growth Initiatives Leawood, Kansas and Columbus, Georgia The Combined Company After Closing the Transaction AMC is one of the nations premier entertainment companies with 5,426 screens and the] [AMC Entertainment Holdings, Inc. to Acquire Carmike Cinemas, Inc. March 4, 2016 + Significant Value Creation for AMC Shareholders Accretive to free cash flow per share in first full year Increases opportunity for deployment of growth initiatives Expected annual cost synergies of approximately $35 million Quarterly dividend maintained Receive founder shares in National CineMedia, LLC to become largest founding shareholder] [Item 7.01 Regulation FD Disclosure.]

By info| 2016-03-26T17:50:17+00:00 March 4th, 2016|Categories: AMC, Chinese Stocks, Webplus ver|Tags: 0001411579, 2016-03-04, 7830, 8-K, AMC, SERVICES-MOTION PICTURE THEATERS|0 Comments

EGT [Entertainment Gaming Asia] 8-K: (Original Filing)

[LEASE OF MACHINES AGREEMENT THIS AGREEMENT BETWEEN ELIXIR GAMING TECHNOLOGIES (CAMBODIA) LIMITED nd EGT NAGAWORLD LIMITED Venue Owner Party Partie (each a “ WHEREAS: (A) (B) The Consolidation Agreement shall expire on 29 February 2016. The Venue Owner intends to lease the Machines from EGT and operate all of them within NagaWorld itself. (C) EGT agrees to lease, and the] []

By info| 2016-04-02T03:44:17+00:00 March 4th, 2016|Categories: Chinese Stocks, EGT, SEC Original|Tags: 0001004673, 2016-03-04, 3990, 8-K, EGT, MISCELLANEOUS MANUFACTURING INDUSTRIES|0 Comments

EGT [Entertainment Gaming Asia] 8-K: LEASE OF MACHINES AGREEMENT THIS AGREEMENT BETWEEN ELIXIR

[LEASE OF MACHINES AGREEMENT THIS AGREEMENT BETWEEN ELIXIR GAMING TECHNOLOGIES (CAMBODIA) LIMITED nd EGT NAGAWORLD LIMITED Venue Owner Party Partie (each a “ WHEREAS: (A) (B) The Consolidation Agreement shall expire on 29 February 2016. The Venue Owner intends to lease the Machines from EGT and operate all of them within NagaWorld itself. (C) EGT agrees to lease, and the] []

By info| 2016-04-02T03:45:11+00:00 March 4th, 2016|Categories: Chinese Stocks, EGT, Webplus ver|Tags: 0001004673, 2016-03-04, 3990, 8-K, EGT, MISCELLANEOUS MANUFACTURING INDUSTRIES|0 Comments

CBPO [China Biologic Products] 8-K: (Original Filing)

[Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,500,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT March 1, 2016 March 1, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule I Underwriter Shares Common Stock] [Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,870,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) AMENDED AND RESTATED UNDERWRITING AGREEMENT March 2, 2016 March 2, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule] [4 March China Biologic Products, Inc. Re: Registration Statement on Form S-3 Ladies and Gentlemen: Registration Statement Company Commission Act We have examined the registration statement on Form S-3 (No. 333-204761) (the “ Common Stock Preferred Stock Prospectus Prospectus Supplement Selling Stockholders Shares Underwriting Agreement We understand that 3,870,000 shares of Common Stock are to be sold by certain stockholders] [China Biologic Announces Secondary Offering of Common Stock BEIJING, China – March 1, 2016 The shares to be sold in this offering represent approximately 13.2 percent of the Company’s current outstanding shares of common stock. Morgan Stanley & Co. International plc is acting as the sole underwriter for the offering. prospectus@morganstanley.com This press release shall not constitute an offer to] [China Biologic Announces Pricing of Secondary Offering of Common Stock BEIJING, China – March 2, 2016 China Biologic will not sell any shares of common stock in the offering and will not receive any proceeds from the sale of the Purchased Shares or the Additional Shares. prospectus@morganstanley.com This press release shall not constitute an offer to sell or the solicitation] []